As expected
”Given the positive safety and tolerability profile we have seen with PAT-DX1 to date, we remain confident that the remaining animal toxicology studies will support the advancement of PAT-DX1 into the clinic next year.”
we are truly on our way to clinic and with the Tox being pretty much a sure thing(the big boys will know this too) then I would say these levels are soon to be in the rear view mirror
I thought the Ann late last week would be the start of news flow, long may it continue with lots of left field plays I’m sure the very competent BOD are working on in the background
As expected ”Given the positive safety and tolerability profile...
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(14.3%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $6.022K | 2.007M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 24652453 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 25089307 | 16 |
View Market Depth
| Last trade - 15.21pm 10/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |